Patent SG-11201907242T-A (SG)
Title: IFN-γ-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF
Inventor: KWON BYOUNG
IPC: C07K7/06
Filed: 2018-02-09
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 August 2018 (16.08.2018) WIPO I PCT omit VIII °nolo milli woo 1111 X10111111 oimIE (10) International Publication Number WO 2018/146549 Al (2006.01) (2006.01) (2006.01) (51) International Patent Classification: C07K 16/30 (2006.01) A61P 35/04 C07K 7/06 (2006.01) A61P 35/02 A61K 39/395 (2006.01) A61P 37/02 A61K 38/17 (2006.01) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: (22) International Filing Date: PCT/IB2018/000201 Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) 09 February 2018 (09.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/457,422 10 February 2017 (10.02.2017) US (71) Applicant: EUTILEX CO., LTD. [KR/KR]; Suite #1401 Daeryung Technotown 17 Cha, Gasan Digital 1-ro 25, Geumcheon-gu, Seoul 08594 (KR). (72) Inventors: KWON, Byoung, S.; c/o Eutilex Co., Ltd, Suite #1401 Daeryung Technotown 17 Cha, Gasan Digital 1- ro 25, Geumcheon-gu, Seoul 08594 (KR). LEE, Seoung- joo; c/o Eutilex Co., Ltd, Suite #1401 Daeryung Techno- town 17 Cha, Gasan Digital 1-ro 25, Geumcheon-gu, Seoul 08594 (KR). LEE, Joong, Won; c/o Eutilex Co., Ltd, Suite #1401 Daeryung Technotown 17 Cha, Gasan Digital 1-ro 25, Geumcheon-gu, Seoul 08594 (KR). LEE, Seunghyun; c/o Eutilex Co., Ltd, Suite #1401 Daeryung Technotown 17 Cha, Gasan Digital 1-ro 25, Geumcheon-gu, Seoul 08594 (KR). (74) Agent: CHANG, Duck Soon; Kim & Chang, Seyang B/D, 39 Sajikno-8-gil, Jongno-gu, Seoul 03170 (KR). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: IFN-y-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF 00 (57) : Provided are IFN-y-Inducible Regulatory T Cell Convertible Anti-Cancer (IRTCA) antibodies and antigen-binding O fragment thereof that bind to an activation-inducible TNFR (AITR) polypeptide. Various in vitro and in vivo methods and compositions related to IRTCA antibodies described herein are also provided. Methods include, for example, changing cytokine secretion from T 0 cells in vivo or in vitro and prevention and/or therapeutic treatment of cancer using an IRTCA antibody or fragment thereof.